Baron Funds' "Baron Health Care Fund" Q2 2024 investor letter reported a 2.55% decline compared to benchmarks. The fund highlighted Arcellx, Inc. (NASDAQ:ACLX) as a top pick, with significant growth potential in cell therapies.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing